{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:30:30Z","timestamp":1793503830832,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010248","name":"Zhejiang Province Public Welfare Technology Application Research Project","doi-asserted-by":"publisher","award":["2024yc-cxfz30013"],"award-info":[{"award-number":["2024yc-cxfz30013"]}],"id":[{"id":"10.13039\/501100010248","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicon"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.toxicon.2026.109215","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:37:50Z","timestamp":1784097470000},"page":"109215","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Repurposing marimastat as a broad-spectrum small-molecule inhibitor for snakebite envenoming: From oncology trials to the development of field-ready interventions"],"prefix":"10.1016","volume":"282","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5188-2283","authenticated-orcid":false,"given":"Hua","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.toxicon.2026.109215_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105600","article-title":"Development of an oral regimen of unithiol for the treatment of snakebite envenoming: a phase 1 open-label dose-escalation safety trial and pharmacokinetic analysis in healthy Kenyan adults","volume":"113","author":"Abouyannis","year":"2025","journal-title":"EBioMedicine"},{"key":"10.1016\/j.toxicon.2026.109215_bib2","doi-asserted-by":"crossref","first-page":"5964","DOI":"10.1038\/s41467-020-19981-6","article-title":"A therapeutic combination of two small molecule toxin inhibitors provides pancontinental preclinical efficacy against viper snakebite","volume":"11","author":"Albulescu","year":"2020","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.toxicon.2026.109215_bib3","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3390\/toxins17070328","article-title":"Snake venom metalloproteinases from puff adder and saw-scaled viper venoms cause cytotoxic effects in human keratinocytes","volume":"17","author":"Bartlett","year":"2025","journal-title":"Toxins"},{"issue":"12","key":"10.1016\/j.toxicon.2026.109215_bib4","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1038\/sj.bjc.6600310","article-title":"Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial","volume":"86","author":"Bramhall","year":"2002","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.toxicon.2026.109215_bib5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/pro.2400","article-title":"Architecture and function of metallopeptidase catalytic domains","volume":"23","author":"Cerd\u00e0-Costa","year":"2014","journal-title":"Protein Sci."},{"key":"10.1016\/j.toxicon.2026.109215_bib6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.toxicon.2022.08.017","article-title":"Keel venom: rhabdophis subminiatus (Red-Necked Keelback) venom pathophysiologically affects diverse blood clotting pathways","volume":"218","author":"Chowdhury","year":"2022","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2026.109215_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1328950","article-title":"Snakebite drug discovery: high-throughput screening to identify novel snake venom metalloproteinase toxin inhibitors","volume":"14","author":"Clare","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.toxicon.2026.109215_bib8","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.110419.3.sa3","article-title":"Repurposed small molecule toxin inhibitors neutralise a diversity of venoms from the neotropical viperid snake genus bothrops","author":"Clare","year":"2026","journal-title":"eLife"},{"key":"10.1016\/j.toxicon.2026.109215_bib9","article-title":"A drug combination therapy consisting of toxin phospholipase A2 and metalloproteinase inhibitors provides preclinical protection against north American crotalid snakebite envenoming","author":"Dawson","year":"2025","journal-title":"bioRxiv"},{"issue":"2","key":"10.1016\/j.toxicon.2026.109215_bib10","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3390\/pharmaceutics17020212","article-title":"Pharmacokinetics of snake antivenom following intravenous and intramuscular administration in envenomed large animal model","volume":"17","author":"Gamulin","year":"2025","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.toxicon.2026.109215_bib11","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1385\/MB:24:2:157","article-title":"Structural aspects of the metzincin clan of metalloendopeptidases","volume":"24","author":"Gomis-R\u00fcth","year":"2003","journal-title":"Mol. Biotechnol."},{"key":"10.1016\/j.toxicon.2026.109215_bib12","article-title":"Snakebite envenoming","volume":"3","author":"Guti\u00e9rrez","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.toxicon.2026.109215_bib14","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.109112.3.sa3","article-title":"Purified zymogens reveal mechanisms of snake venom metalloproteinase auto-activation","author":"Hall","year":"2026","journal-title":"eLife"},{"key":"10.1016\/j.toxicon.2026.109215_bib13","doi-asserted-by":"crossref","first-page":"7812","DOI":"10.1038\/s41467-023-43510-w","article-title":"Repurposed drugs and their combinations prevent morbidity-inducing dermonecrosis caused by diverse cytotoxic snake venoms","volume":"14","author":"Hall","year":"2023","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.toxicon.2026.109215_bib15","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.toxicon.2006.11.020","article-title":"Neutralization of the haemorrhagic activities of viperine snake venoms and venom metalloproteinases using synthetic peptide inhibitors and chelators","volume":"49","author":"Howes","year":"2007","journal-title":"Toxicon"},{"issue":"12","key":"10.1016\/j.toxicon.2026.109215_bib16","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3390\/toxins17120571","article-title":"Differential effects of marimastat and prinomastat on the metalloprotease activity of various snake venoms","volume":"17","author":"Khatibi","year":"2025","journal-title":"Toxins"},{"issue":"2","key":"10.1016\/j.toxicon.2026.109215_bib17","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3390\/tropicalmed3020042","article-title":"Recent advances in next generation snakebite antivenoms","volume":"3","author":"Knudsen","year":"2018","journal-title":"Trop. Med. Infect. Dis."},{"issue":"5","key":"10.1016\/j.toxicon.2026.109215_bib18","doi-asserted-by":"crossref","DOI":"10.1186\/ar2315","article-title":"Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study","volume":"9","author":"Krzeski","year":"2007","journal-title":"Arthritis Res. Ther."},{"issue":"5","key":"10.1016\/j.toxicon.2026.109215_bib19","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.3390\/cells9051076","article-title":"Structure and function of human matrix metalloproteinases","volume":"9","author":"Laronha","year":"2020","journal-title":"Cells"},{"issue":"9","key":"10.1016\/j.toxicon.2026.109215_bib20","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3390\/toxins8090248","article-title":"Varespladib (LY315920) appears to be a potent, broad-spectrum, inhibitor of snake venom phospholipase A2 and a possible pre-referral treatment for envenomation","volume":"8","author":"Lewin","year":"2016","journal-title":"Toxins (Basel)"},{"issue":"11","key":"10.1016\/j.toxicon.2026.109215_bib21","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3390\/toxins14110783","article-title":"Varespladib in the treatment of snakebite envenoming: development history and preclinical evidence supporting advancement to clinical trials in patients bitten by venomous snakes","volume":"14","author":"Lewin","year":"2022","journal-title":"Toxins"},{"key":"10.1016\/j.toxicon.2026.109215_bib22","series-title":"TOCSINS drug trials","year":"2020"},{"key":"10.1016\/j.toxicon.2026.109215_bib23","series-title":"The High-Stakes Quest to Make Snakebites Survivable Took Leaps Forward This Year, with Promising New Avenues to Safer Antivenoms","author":"Malloy","year":"2025"},{"key":"10.1016\/j.toxicon.2026.109215_bib24","series-title":"Marimastat. Massive bio medical knowledge glossary","year":"2026"},{"key":"10.1016\/j.toxicon.2026.109215_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.toxcx.2022.100118","article-title":"In vitro and in vivo preclinical venom inhibition assays identify metalloproteinase inhibiting drugs as potential future treatments for snakebite envenoming by dispholidus typus","volume":"14","author":"Menzies","year":"2022","journal-title":"Toxicon X"},{"issue":"1","key":"10.1016\/j.toxicon.2026.109215_bib26","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1046\/j.1365-2125.1998.00639.x","article-title":"Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers","volume":"45","author":"Millar","year":"1998","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.toxicon.2026.109215_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.toxcx.2020.100052","article-title":"Snake venom metalloproteinases (SVMPs): a structure\u2013function update","volume":"7","author":"Olaoba","year":"2020","journal-title":"Toxicon X"},{"issue":"1","key":"10.1016\/j.toxicon.2026.109215_bib28","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/s43856-025-00900-z","article-title":"Preclinical evaluation of small molecule inhibitors as early intervention therapeutics against Russell's viper envenoming in India","volume":"5","author":"Rudresha","year":"2025","journal-title":"Commun. Med."},{"issue":"1","key":"10.1016\/j.toxicon.2026.109215_bib29","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/bph.14186","article-title":"Monoclonal antibodies against metzincin targets","volume":"176","author":"Santamaria","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.toxicon.2026.109215_bib30","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1749-6632.1999.tb07689.x","article-title":"Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials","volume":"878","author":"Shalinsky","year":"1999","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"6","key":"10.1016\/j.toxicon.2026.109215_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2024.100779","article-title":"Assessing target specificity of the small molecule inhibitor MARIMASTAT to snake venom toxins: a novel application of thermal proteome profiling","volume":"23","author":"Smith","year":"2024","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.toxicon.2026.109215_bib32","series-title":"Novel Strategies to Treat Snake Venom Induced Muscle Damage","author":"Sonalane","year":"2024"},{"issue":"12","key":"10.1016\/j.toxicon.2026.109215_bib33","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1517\/13543784.9.12.2913","article-title":"Marimastat: the clinical development of a matrix metalloproteinase inhibitor","volume":"9","author":"Steward","year":"2000","journal-title":"Expert Opin. Invest. Drugs"},{"issue":"11","key":"10.1016\/j.toxicon.2026.109215_bib34","doi-asserted-by":"crossref","first-page":"4395","DOI":"10.1096\/fj.13-233601","article-title":"Crystal structure of full-length human collagenase 3 (MMP-13) with peptides in the active site defines exosites in the catalytic domain","volume":"27","author":"Stura","year":"2013","journal-title":"FASEB J."},{"key":"10.1016\/j.toxicon.2026.109215_bib35","unstructured":"Tocris Bioscience. Marimastat (Cat. No. 2631). Tocris Bioscience Product Information. Available from::https:\/\/www.tocris.com\/products\/marimastat_2631 [Accessed 10 June 2026]."},{"issue":"9","key":"10.1016\/j.toxicon.2026.109215_bib36","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3390\/biomedicines8090297","article-title":"Neutralizing effects of small molecule inhibitors and metal chelators on coagulopathic viperinae snake venom toxins","volume":"8","author":"Xie","year":"2020","journal-title":"Biomedicines"},{"issue":"5","key":"10.1016\/j.toxicon.2026.109215_bib37","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.3390\/molecules27051733","article-title":"Efficacy and limitations of chemically diverse small-molecule enzyme-inhibitors against the synergistic coagulotoxic activities of bitis viper venoms","volume":"27","author":"Youngman","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.toxicon.2026.109215_bib38","article-title":"The metalloproteinase inhibitor marimastat improves skeletal muscle regeneration when administered intravenously after myonecrosis induced by the venom of Bothrops asper","author":"Zamora","year":"2026","journal-title":"bioRxiv"}],"container-title":["Toxicon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041010126002333?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041010126002333?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:52:52Z","timestamp":1788457972000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041010126002333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":38,"alternative-id":["S0041010126002333"],"URL":"https:\/\/doi.org\/10.1016\/j.toxicon.2026.109215","relation":{},"ISSN":["0041-0101"],"issn-type":[{"value":"0041-0101","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repurposing marimastat as a broad-spectrum small-molecule inhibitor for snakebite envenoming: From oncology trials to the development of field-ready interventions","name":"articletitle","label":"Article Title"},{"value":"Toxicon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.toxicon.2026.109215","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109215"}}